PE20211267A1 - Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina - Google Patents
Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozinaInfo
- Publication number
- PE20211267A1 PE20211267A1 PE2020000563A PE2020000563A PE20211267A1 PE 20211267 A1 PE20211267 A1 PE 20211267A1 PE 2020000563 A PE2020000563 A PE 2020000563A PE 2020000563 A PE2020000563 A PE 2020000563A PE 20211267 A1 PE20211267 A1 PE 20211267A1
- Authority
- PE
- Peru
- Prior art keywords
- heart failure
- dapagliflozin
- methods
- ejection fraction
- treatment
- Prior art date
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 3
- 229960003834 dapagliflozin Drugs 0.000 title abstract 3
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 7
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 2
- 230000034994 death Effects 0.000 abstract 2
- 231100000517 death Toxicity 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 230000003862 health status Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893849P | 2019-08-30 | 2019-08-30 | |
| US201962930673P | 2019-11-05 | 2019-11-05 | |
| US201962946625P | 2019-12-11 | 2019-12-11 | |
| US202062960756P | 2020-01-14 | 2020-01-14 | |
| US202062969181P | 2020-02-03 | 2020-02-03 | |
| US202062985407P | 2020-03-05 | 2020-03-05 | |
| PCT/EP2020/056211 WO2021037400A1 (en) | 2019-08-30 | 2020-03-09 | Methods of treating heart failure with reduced ejection fraction with dapagliflozin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211267A1 true PE20211267A1 (es) | 2021-07-19 |
Family
ID=69784449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000563A PE20211267A1 (es) | 2019-08-30 | 2020-03-09 | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10973836B2 (https=) |
| EP (1) | EP4021507A1 (https=) |
| JP (4) | JP7756487B2 (https=) |
| KR (3) | KR102359799B1 (https=) |
| CN (1) | CN112752582A (https=) |
| AU (4) | AU2020202887B2 (https=) |
| BR (1) | BR112020008705A2 (https=) |
| CA (1) | CA3079175A1 (https=) |
| CL (1) | CL2020001335A1 (https=) |
| CR (1) | CR20200224A (https=) |
| IL (1) | IL274020A (https=) |
| JO (1) | JOP20200098A1 (https=) |
| MX (2) | MX2020005388A (https=) |
| PE (1) | PE20211267A1 (https=) |
| PH (1) | PH12020551141A1 (https=) |
| SG (1) | SG11202003971RA (https=) |
| TW (3) | TW202504616A (https=) |
| WO (1) | WO2021037400A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53175A (fr) | 2018-07-19 | 2021-05-26 | Astrazeneca Ab | Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci |
| PE20211267A1 (es) * | 2019-08-30 | 2021-07-19 | Astrazeneca Ab | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina |
| CA3180674A1 (en) * | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
| WO2022144465A1 (en) * | 2021-01-04 | 2022-07-07 | Charité-Universitätsmedizin Berlin | Sotagliflozin for improving left atrial function |
| US20250108065A1 (en) | 2022-01-26 | 2025-04-03 | Astrazeneca Ab | Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin |
| JP7396579B2 (ja) * | 2022-01-31 | 2023-12-12 | 壽製薬株式会社 | 左室駆出率が保たれた心不全に対する医薬組成物 |
| WO2023175573A1 (en) * | 2022-03-17 | 2023-09-21 | Zydus Lifesciences Limited | Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor |
| WO2023192848A1 (en) * | 2022-03-28 | 2023-10-05 | University Of Maryland, Baltimore | Methods and compositions for the treatment of stroke |
| AU2023331475A1 (en) * | 2022-09-01 | 2025-04-17 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
| CN120390636A (zh) * | 2022-12-20 | 2025-07-29 | 斯法姆公司 | 包含钠-葡萄糖协同转运蛋白2抑制剂和血管紧张素ⅱ受体阻滞剂的口服药物制剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| AR059489A1 (es) | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| JP2011506363A (ja) | 2007-12-11 | 2011-03-03 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全の処置および／または予防用のオキサゾリジノン類 |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP3160948B1 (en) | 2014-06-30 | 2018-10-24 | Astrazeneca AB | Benzoxazinone amides as mineralocorticoid receptor modulators |
| CN106714840A (zh) * | 2014-09-25 | 2017-05-24 | 阿斯利康(瑞典)有限公司 | 用于治疗肝病的ω‑3脂肪酸和SGLT‑2抑制剂的组合 |
| BR112018016001A2 (en) * | 2016-03-16 | 2018-12-18 | Boehringer Ingelheim International Gmbh | pharmaceutical composition, treatment methods and uses thereof |
| WO2018043463A1 (ja) * | 2016-08-30 | 2018-03-08 | 国立大学法人新潟大学 | 老化細胞除去薬 |
| WO2018142422A1 (en) | 2017-02-02 | 2018-08-09 | Indoco Remedies Limited | Process for the preparation of dapagliflozin |
| KR101943382B1 (ko) | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| MA53175A (fr) | 2018-07-19 | 2021-05-26 | Astrazeneca Ab | Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci |
| PE20211267A1 (es) | 2019-08-30 | 2021-07-19 | Astrazeneca Ab | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina |
| US12409186B2 (en) * | 2020-07-27 | 2025-09-09 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
-
2020
- 2020-03-09 PE PE2020000563A patent/PE20211267A1/es unknown
- 2020-03-09 CR CR20200224A patent/CR20200224A/es unknown
- 2020-03-09 KR KR1020207012588A patent/KR102359799B1/ko active Active
- 2020-03-09 KR KR1020247038499A patent/KR20240166611A/ko active Pending
- 2020-03-09 CA CA3079175A patent/CA3079175A1/en active Pending
- 2020-03-09 WO PCT/EP2020/056211 patent/WO2021037400A1/en not_active Ceased
- 2020-03-09 KR KR1020217014553A patent/KR20220044234A/ko not_active Ceased
- 2020-03-09 JP JP2020524303A patent/JP7756487B2/ja active Active
- 2020-03-09 US US16/812,745 patent/US10973836B2/en active Active
- 2020-03-09 CN CN202080000531.4A patent/CN112752582A/zh active Pending
- 2020-03-09 SG SG11202003971RA patent/SG11202003971RA/en unknown
- 2020-03-09 EP EP20710490.2A patent/EP4021507A1/en active Pending
- 2020-03-09 JO JOP/2020/0098A patent/JOP20200098A1/ar unknown
- 2020-03-09 MX MX2020005388A patent/MX2020005388A/es unknown
- 2020-03-09 BR BR112020008705A patent/BR112020008705A2/pt not_active Application Discontinuation
- 2020-03-09 AU AU2020202887A patent/AU2020202887B2/en active Active
- 2020-04-19 IL IL274020A patent/IL274020A/en unknown
- 2020-04-30 TW TW113137483A patent/TW202504616A/zh unknown
- 2020-04-30 TW TW109114687A patent/TWI786398B/zh active
- 2020-04-30 TW TW111145734A patent/TWI859649B/zh active
- 2020-05-01 PH PH12020551141A patent/PH12020551141A1/en unknown
- 2020-05-20 CL CL2020001335A patent/CL2020001335A1/es unknown
- 2020-07-13 MX MX2022008018A patent/MX2022008018A/es unknown
-
2021
- 2021-02-25 US US17/184,746 patent/US11903955B2/en active Active
- 2021-08-10 AU AU2021215150A patent/AU2021215150B2/en active Active
-
2022
- 2022-12-06 JP JP2022194700A patent/JP7494277B2/ja active Active
-
2023
- 2023-07-31 AU AU2023210548A patent/AU2023210548B2/en active Active
-
2024
- 2024-01-11 US US18/410,094 patent/US20240216404A1/en active Pending
- 2024-05-22 JP JP2024083232A patent/JP2024119842A/ja active Pending
-
2025
- 2025-04-04 JP JP2025062458A patent/JP2025108488A/ja active Pending
- 2025-06-17 AU AU2025204486A patent/AU2025204486A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211267A1 (es) | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| DOP2021000273A (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| CL2023001351A1 (es) | Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil. | |
| CL2021003374A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| CO2020010342A2 (es) | Composiciones de arni de 17 β -hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas | |
| BR112022004699A2 (pt) | Vs-6063 em combinação com ch5126766 para o tratamento de câncer | |
| CL2013001247A1 (es) | Metodo de tratamiento y/o prevencion del estres oxidativo, estres vascular y/o disfuncion endotelial en pacientes no diabeticos o en pacientes con diabetes tales como de tipo 1, diabetes autoinmune latente del adulto (dala) y diabetes de tipo 2, que comprende administrar linagliptina; compuesto linagliptina, inhibidor de dpp-4. | |
| MX351865B (es) | Composiciones de raav-guanilato ciclasa y metodos para el tratamiento de la amaurosis congenita de leber 1 (lca1). | |
| MX366343B (es) | Terapia genetica. | |
| MX2015012520A (es) | Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion. | |
| MX2021012184A (es) | Terapias genicas para trastornos lisosomales. | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| CR20180433A (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
| EA201690660A1 (ru) | Соединения и способы на основе двойного агониста гип и гпп-1 | |
| WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| CR20130409A (es) | Novedosos derivados de azabencimidazolcíclico útiles como agentes antidiabéticos | |
| MX2025003918A (es) | Tratamiento de la disfuncion sistolica | |
| MX2021011958A (es) | Terapias genicas para trastornos lisosomales. | |
| MX2021000363A (es) | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. | |
| BR112022007721A2 (pt) | Método para o tratamento da demência | |
| MX2021003904A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. |